---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-046698"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:43:09.529328+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TELA Bio preliminary Q1 revenue $11.9M, up 45% YoY; cash $30.1M

## Summary
- Revenue estimated at $11.9M for Q1 2023 vs $8.2M in Q1 2022, a 45% increase.
- Cash and equivalents $30.1M at March 31, 2023, down from $42.0M at Dec 31, 2022.
- Results are preliminary and subject to change upon completion of quarter-end closing.

## SEC filing metadata
- accession: 0001104659-23-046698
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465923046698/0001104659-23-046698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465923046698/tm232660d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-046698
- JSON: https://secwatch.observer/filing/0001104659-23-046698.json
- Plain text: https://secwatch.observer/filing/0001104659-23-046698.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported the first quarter ended March 31, 2023 results: revenue $11.9 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $11.9 million
  - Result: preliminary results
  source text: Revenue for the three months ended March 31, 2023 is estimated to be $11.9 million, compared to $8.2 million over the corresponding period of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465923046698/0001104659-23-046698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.